An extract of Urtica dioica L. mitigates obesity induced insulin resistance in mice skeletal muscle via protein phosphatase 2A (PP2A)

Diana N. Obanda  
*Pennington Biomedical Research Center*

David Ribnicky  
*Rutgers University–New Brunswick*

Yongmei Yu  
*Pennington Biomedical Research Center*

Jacqueline Stephens  
*Pennington Biomedical Research Center*

William T. Cefalu  
*Pennington Biomedical Research Center*

Follow this and additional works at: [https://digitalcommons.lsu.edu/biosci_pubs](https://digitalcommons.lsu.edu/biosci_pubs)

**Recommended Citation**

This Article is brought to you for free and open access by the Department of Biological Sciences at LSU Digital Commons. It has been accepted for inclusion in Faculty Publications by an authorized administrator of LSU Digital Commons. For more information, please contact [ir@lsu.edu](mailto:ir@lsu.edu).
An extract of *Urtica dioica* L. mitigates obesity induced insulin resistance in mice skeletal muscle via protein phosphatase 2A (PP2A)

Diana N. Obanda¹, David Ribnicky², Yongmei Yu¹, Jacqueline Stephens¹ & William T. Cefalu¹

The leaf extract of *Urtica dioica* L. (UT) has been reported to improve glucose homeostasis in vivo, but definitive studies on efficacy and mechanism of action are lacking. We investigated the effects of UT on obesity-induced insulin resistance in skeletal muscle. Male C57BL/6J mice were divided into three groups: low-fat diet (LFD), high-fat diet (HFD) and HFD supplemented with UT. Body weight, body composition, plasma glucose and plasma insulin were monitored. Skeletal muscle (gastrocnemius) was analyzed for insulin sensitivity, ceramide accumulation and the post translational modification and activity of protein phosphatase 2A (PP2A). PP2A is activated by ceramides and dephosphorylates Akt. C2C12 myotubes exposed to excess free fatty acids with or without UT were also evaluated for insulin signaling and modulation of PP2A. The HFD induced insulin resistance, increased fasting plasma glucose, enhanced ceramide accumulation and PP2A activity in skeletal muscle. Supplementation with UT improved plasma glucose homeostasis and enhanced skeletal muscle insulin sensitivity without affecting body weight and body composition. In myotubes, UT attenuated the ability of FFAs to induce insulin resistance and PP2A hyperactivity without affecting ceramide accumulation and PP2A expression. UT decreased PP2A activity through posttranslational modification that was accompanied by a reduction in Akt dephosphorylation.

Obesity induced insulin resistance is a key pathophysiologic feature of type 2 diabetes mellitus (T2DM). Progression of insulin resistance into overt T2DM can be prevented or delayed by timely intervention. Treatment of subjects with insulin resistance is directed at increasing insulin sensitivity. Reduction in calorie intake and increase in physical activity are effective but difficult to maintain in the long-term. Therefore, conventional medications that address insulin resistance are an option in clinical medicine and are a major focus for drug development.

Insulin resistance is induced by the accumulation of lipid metabolites from excess fat in insulin sensitive cells. Excess dietary carbohydrate not stored as glycogen or oxidized for energy is converted to fat by de novo lipogenesis. Among the fatty acid derived metabolites, ceramides are most active in negatively regulating insulin signaling. The primary target of ceramides in the insulin signaling pathway is Akt whose activity state is regulated by serine/threonine phosphorylation. Ceramides activate cytosolic protein phosphatase 2A (PP2A) a serine/threonine phosphatase that dephosphorylates Akt leaving it inactivated and unable to mediate insulin stimulated glucose uptake and metabolism. Thus, interventions that may modulate this pathway may be useful for treatment for insulin resistance.

Because some conventional medications marketed for insulin resistance have troublesome side effects, there is increasing interest in natural complementary and alternative therapies from plants. Use of over the counter botanical agents is extensively practiced by a large number of patients. Plants have traditionally been a rich source of medicinal compounds for many indications. A number of botanicals have shown promise as therapies for insulin resistance and hyperglycemia. Among these is the extract of *Urtica dioica* L. (UT) or stinging nettle (family Urticaceae) whose blood glucose lowering effect has been historically noted and supported by recent animal studies and in vitro studies. However, the mechanism(s) that contribute to these positive systemic effects of UT are not yet well understood. Therefore, the present study was designed to investigate the effects of UT on obesity-induced insulin resistance in skeletal muscle.
UT are largely unknown and bioactive components are not elucidated. Despite this paucity of data on efficacy and mechanism(s), UT dietary supplements are widely available in the United States. The acceptance and widespread use of botanical supplements by the general public justifies research in investigating their mechanisms of action. The overall objective of the current study was to examine the efficacy and mechanism(s) of action of UT as a dietary supplement for ameliorating diet induced insulin resistance in skeletal muscle.

In this study, we hypothesized that UT maintains insulin sensitivity through mechanisms that enhance Akt phosphorylation despite the accumulation of ceramides in skeletal muscle. Increased Akt phosphorylation can be achieved by either increase in the activities of kinases that phosphorylate it or by a decrease in activities of phosphatases that modulate its activity. Based on previous reports that have demonstrated that PP2A inhibition with okadaic acid or a neutralizing antibody increased Akt activity14–17, we determined the effect of UT on the activity of PP2A. Our observations from two model systems that include in vitro and in vivo studies demonstrate that supplementation with UT attenuates lipid induced PP2A hyperactivity and enhances insulin sensitivity and insulin stimulated glucose metabolism in skeletal muscle. These studies strongly suggest that UT has metabolically beneficial effects in skeletal muscle and indicate its potential as a botanical supplement for metabolic disease states such as insulin resistance.

Materials and Methods
Source and preparation and of plant extract. _Urtica dioica_ L. (UT) was harvested as the total herb above the root mass and a voucher specimen was produced by the Botanical Research Center and deposited in the Chrysler Herbarium at Rutgers University. The plant was harvested in New Jersey. Geographic coordinates of the botanical collection site are 40°36′03.9″N 74°40′30.1″W. The freeze-dried plant was stored at −20 °C. Source and preparation and of plant extract.

Animals. All experiments and procedures were performed in accordance with relevant guidelines and regulations of the Pennington Biomedical Research Center. All animal experiments and procedures were performed in accordance to a protocol approved by the Institutional Animal Care and Use Committee (IACUC) of the Pennington Biomedical Research Center. Thirty three (33) male C57BL/6J mice at 5 weeks age were ordered from Jackson Laboratories, Inc. (Bar Harbor, Maine, USA). After one week quarantine followed by baseline feeding of all mice for an additional week on the low fat diet (Research Diets D12450B), mice were randomly divided into a low-fat diet group (LFD as negative control, n = 11), high-fat diet group (HFD, Research Diets D12492) as positive control, n = 11) and HFD supplemented with UT group (n = 11). UT extract was incorporated into the high-fat diet at 0.5% w/w. Mice were singly housed in shoebox cages with corn cob bedding in controlled environmental conditions (22 °C), 12 hour light dark cycle with _ad libitum_ access to food and water. Food intake (the difference of weight administered and leftover plus spillage) and body weight were monitored and recorded weekly.

Body composition measurement. Body composition was determined by nuclear magnetic resonance (NMR-Bruker, Newark, DE, USA) as previously shown18. Body fat mass, muscle mass and free fluid were recorded at baseline (week 0) and at weeks 6 and 12 of feeding.

Blood chemistry. Fasting (4h) plasma glucose and insulin were determined at baseline and after 6 and 12 weeks of treatment. Insulin levels were determined by a mouse insulin enzyme linked immunosorbent assay (ELISA) kit (Crystal Chem, Downers Grove, IL). Blood glucose was measured using a portable glucometer (Millipitas, CA, USA). The intraperitoneal insulin tolerance test (IPITT) and intraperitoneal glucose tolerance test (IPGTT) were performed at week 10 and week 12, feeding regimen as described previously18. For glucose tolerance tests, mice were fasted for 6h prior to injections of 2 g glucose/kg body weight. For insulin tolerance tests, mice received 0.5 U of insulin/kg body weight (Humulin; Eli Lilly, Indianapolis, IN). Blood glucose concentrations were measured on the nicked tail vein at time 0 (baseline), 15, 30, 60 and 120 min after glucose or insulin injections. HOMA-IR was used as a measure of insulin resistance and was calculated from fasting insulin and glucose concentrations. Blood chemistry was measured using the trapezoidal method, the area under curves (AUC) showing the change of blood glucose level over the course of IPGTT and IPITT were calculated.

Tissue collection and processing. At 18 weeks of age, following 12 weeks of treatment each group was divided into basal and insulin-stimulated subgroups. The basal sub group (n = 5), were given an intraperitoneal injection of saline after 6 hours fasting while the insulin-stimulated sub group (n = 6) was given insulin at a dose of 2 U/kg body weight. After 10 minutes, animals were euthanized by CO2 inhalation followed by cervical dislocation and decapitation. Blood and tissue were snap frozen in liquid nitrogen and stored at −80 °C for later analysis.

Tissue processing and immunoblotting. 50 mg gastrocnemius muscle was dissected and homogenized in Buffer A (1% Triton X-100, 20 mmol Tris (pH 75), 2.5 mmol sodium pyrophosphate, 150 mmol NaCl, 1 mmol EGTA, 1 mmol sodium vanadate, 2 mM beta-glycerophosphate, 1 μg/ml leupeptin, 1 μl/ml aprotinin, 1 μl/ml PMSF) using a PRO 200 homogenizer (PRO Scientific, Oxford, CT, USA). Samples were centrifuged (12000 rpm, 10 min at 4 °C) and protein concentrations of the supernatant determined by the Bio-Rad protein assay kit (Bio-Rad laboratories, Inc. Hercules, CA). Supernatants (80 μg) were resolved by SDS-PAGE and subjected to standard immunoblotting. Protein abundance was detected with antibodies against Akt1, Akt2, phosho-Akt (ser 473), phospho-Akt (Thr 308), AMPKα1, AMPKα2, phospho AMPK (Thr 172) (Millipore, Temecula, CA). Other antibodies were PP2A-A, PP2A-B, PP2A-C (Cat No. SC-80665), methyl PP2A-C (Cat No. SC-81603) and phospho PP2A Tyr 307 (Cat No. SC-12615) all from Santa Cruz Biotecnology, Santa Cruz, CA). Protein
Food intake, body weight, body composition and circulating FFAs.

<table>
<thead>
<tr>
<th></th>
<th>LFD</th>
<th>HFD</th>
<th>HFD/UT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Food intake per day (grams)</td>
<td>2.56 ± 0.81</td>
<td>2.23 ± 0.49</td>
<td>2.26 ± 0.61</td>
</tr>
<tr>
<td>Body weight (grams)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 0</td>
<td>22.02 ± 0.45</td>
<td>21.82 ± 0.46</td>
<td>22.08 ± 0.18</td>
</tr>
<tr>
<td>Week 6</td>
<td>25.68 ± 0.44</td>
<td>30.40 ± 0.70</td>
<td>29.63 ± 0.88</td>
</tr>
<tr>
<td>Week 12</td>
<td>27.99 ± 0.60</td>
<td>35.68 ± 1.15</td>
<td>34.98 ± 1.11</td>
</tr>
<tr>
<td>Body composition (% Fat)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 0</td>
<td>14.96 ± 0.50</td>
<td>15.56 ± 1.06</td>
<td>15.43 ± 0.89</td>
</tr>
<tr>
<td>Week 6</td>
<td>17.33 ± 0.99</td>
<td>25.03 ± 1.48</td>
<td>27.08 ± 2.18</td>
</tr>
<tr>
<td>Week 12</td>
<td>16.23 ± 1.14</td>
<td>28.38 ± 1.14</td>
<td>29.58 ± 2.02</td>
</tr>
<tr>
<td>Body composition (% Muscle)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 0</td>
<td>70.63 ± 0.15</td>
<td>69.91 ± 0.09</td>
<td>70.35 ± 0.23</td>
</tr>
<tr>
<td>Week 6</td>
<td>69.64 ± 0.25</td>
<td>63.07 ± 0.21</td>
<td>62.05 ± 0.13</td>
</tr>
<tr>
<td>Week 12</td>
<td>69.58 ± 0.21</td>
<td>60.90 ± 0.31</td>
<td>59.54 ± 0.20</td>
</tr>
<tr>
<td>Circulating FFAs (week 12) (mmol/l)</td>
<td>0.39 ± 0.1</td>
<td>0.45 ± 0.03</td>
<td>0.44 ± 0.09</td>
</tr>
</tbody>
</table>

Table 1. Food intake, body weight, body composition and circulating FFAs.

expression levels were normalized by tubulin (Santa Cruz Biotechnology, Santa Cruz, CA). Phosphorylation or methylation levels were normalized by the corresponding protein expression. Optical densities of protein bands were analyzed using Image J. Data are expressed as the fold difference of the LFD control group.

Cell culture and in vitro assays. C2C12 myoblasts (ATCC; #CRL-1771) were maintained at 37 °C, 95% air and 5% CO₂ in high glucose DMEM supplemented with 10% FBS serum and antibiotics. For individual experiments, myoblasts were sub-cultured onto 6 well plates, grown to 100% confluence and differentiated into fused myotubes for 4 days by switching to media with 2% horse serum. All cells used were within 5 passages. For cell culture experiments, the dried extract was solubilized in 100% dimethyl sulfoxide (DMSO) at a concentration of 1–10 μg/ml and then diluted into the cell media. A final concentration of 1–10 μg/ml was used to treat cells. Cultures were exposed to FFAs (palmitic acid) conjugated to 1% bovine serum albumin (BSA) and constituted to a final concentration 250 μM with or without 5 μg/ml UT extract or 10 nM okadaic acid (Millipore, Temecula, CA, USA) for 16 hours. For western blotting, 100 nM insulin was added 8 minutes before subsequent collection and analysis. Standard western blotting was performed using 80 μg of cell extracts. Specific antibodies used were the same as those shown above. In all cases, western blot results were verified in three separate experiments. Data are expressed as the fold difference of the vehicle control. The glycogen accumulation assay was performed as described previously. Results were normalized by protein concentration measured by Bio-Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA), and glycogen content was presented as glucose equivalent per well. To determine glucose uptake, after washing with PBS, cells were exposed to 0 or 100 nM insulin in Krebs-Ringer HEPES (KRH) buffer for 15 min followed by an additional incubation for 5 min with 2-deoxy glucose (100 μM, 0.5 μCi). Cells were washed four times with ice-cold KRH buffer, lysed in 250 μl of 0.05 N NaOH and then transferred to vials with scintillation cocktail. Radioactivity in the cells was measured by liquid scintillation counter.

Ceramide Quantification. Lipids were extracted from 30 mg skeletal muscle or cell lysates corresponding to 300 μg protein and total ceramides quantified by tandem mass spectrometry (LCMS/MS) as previously described. PP2A activity. PP2A activity was assayed in lysate corresponding to 300 μg protein processed from cells or muscle tissue. Lysis buffer contained 20 mM imidazole–HCl, 2 mM EDTA, 2 mM EGTA, pH 7.0 with 10 mg/mL each of aprotinin, leupeptin, pepstatin, 1 mM benzamidine, and 1 mM PMSF. Tissue was homogenized on ice and centrifuged at 12,000 rpm for 10 minutes at 4 °C. Cells were sonicated before centrifuging similarly. The supernatants were used to assay PP2A phosphatase activity by a standard kit (EMD Millipore, Temecula CA) according to the manufacturer’s instructions. The intensity of the color reaction was measured at 650 nm on a Bio-rad microplate spectrophotometer.

Statistical analyses. Data are expressed or graphed as mean ± SEM. Statistical significance was determined by comparing means by analysis of variance (ANOVA). Significant differences observed were followed up using the Fisher’s least significant difference (LSD) test. All tests used P < 0.05 as the level of statistical significance.

Results

Supplementation of HFD with_Urtica dioica_ L. does not alter food intake, body weight or body composition. At baseline at six weeks of age, body weights were not statistically different in the three groups. At week 12 the weights had increased by 27.1% in the LFD group, 63.6% in the HFD and 58.4% in the HFD + UT group (Table 1). The HFD and HFD + UT were not significantly different (p = ns, Table 1) but, both were
significantly different from LFD (LFD vs HFD, \(P < 0.01\); LFD vs HFD + UT, \(P < 0.01\)). Daily food consumption was higher in LFD group but was not different between HFD and HFD + UT groups (Table 1). As expected, body composition was similar in the three groups at baseline. After 12 weeks feeding, there was a 12.7% increase in fat mass with LFD, 82.4% increased for the HFD, and 91.7% in the HFD + UT group. Notably, fat mass was not statistically different between HFD and HFD + UT groups. After 12 weeks of treatment, the decrease in percent muscle was 1.49%, for the LFD group, 14.8% for the HFD and a 15.4% decrease was observed in the HFD + UT group. There were no statistical differences in percent muscle between HFD and HFD + UT groups (Table 1). Free fluid mass was not different between the three groups and did not change over the 12 weeks (data not shown).

Supplementation of HFD with *Urtica dioica* L. enhances glucose disposal and insulin signaling in vivo. Fasting plasma glucose and insulin were not different between the three groups at baseline but were significantly increased in the HFD group by week 12 (Fig. 1a,b). Insulin resistance (HOMA-IR) was increased in the HFD (Fig. 1c). Supplementation of the HFD with UT significantly lowered fasting glucose and insulin and improved insulin resistance as assessed by HOMA-IR (HFD vs HFD + UT, \(P < 0.01\); Fig. 1a–c). In a glucose tolerance test, blood glucose levels for the HFD + UT group were significantly lower than those of the HFD group at the 60, 90 and 120 minute intervals (\(P < 0.01\); Fig. 1d). However, both the HFD and HFD + UT groups had significantly higher glucose at these time intervals when compared to the LFD group. In an insulin tolerance test, blood glucose levels in the HFD + UT group were significantly lower than those of the HFD only at the 120 minute interval (\(P < 0.01\)) and were not different from LFD group at all other time intervals (Fig. 1e). The rate of decline of glucose between baseline and 60 minutes after insulin injection was 2.2, 1.3 and 1.54% per minute for LFD, HFD and HFD/UT respectively and was not statistically different between the HFD and the HFD/UT groups. The area under curves (AUC) for glucose tolerance test was not different between the HFD and the HFD/UT groups. However the AUC for insulin tolerance test curve was significantly lower in the HFD/UT group compared to the HFD group (Table 2).

To assess potential direct effects on skeletal muscle, insulin signaling was examined in gastrocnemius muscle from these mice. As shown in Fig. 2, HFD feeding was accompanied by a loss of insulin stimulated Akt serine and threonine phosphorylation. Supplementation of the HFD with UT significantly enhanced insulin stimulated Akt serine and threonine phosphorylation (\(P < 0.01\); Fig. 2). There were no differences in Akt 1 and Akt 2 protein expression levels among the three groups. UT supplementation had no effect on IRS, insulin receptor protein expression, or PI3K and AMPK protein expression and activity (data not shown).
Supplementation of *Urtica dioica* L. to FFA treated C2C12 myotubes reduces the effects of FFA on insulin signaling, glucose uptake and glycogen synthesis. As expected, exposure of myotubes to FFAs induced a decrease in Akt phosphorylation and also decreased insulin induced glycogen synthesis. Co-incubation with FFAs and 5 ug/ml UT or okadaic acid attenuated the ability of FFAs to induce Akt dephosphorylation and reduce glycogen synthesis (Fig. 3a lane 4 vs lane 6 and 10 and Fig. 3b). Incubation with UT only or okadaic acid only enhanced Akt phosphorylation and increased glycogen accumulation compared to the vehicle only treatment (P < 0.05; Fig. 3a lane 2 vs lane 8 and Fig. 3b). Co-incubation with FFAs and 5 ug/ml UT or okadaic acid enhanced glucose uptake (Fig. 3c) compared to vehicle only treatment.

Ceramide levels and PP2A protein activity and expression in skeletal muscle. As expected, skeletal muscle of the HFD group accumulated ceramides and had significantly increased level of PP2A activity compared to the LFD group. UT supplementation did not lower ceramides significantly (Fig. 4a) but lowered PP2A activity significantly compared to the HFD (P < 0.01; Fig. 4b). Protein expression of PP2A subunits A and B between the three groups was not different (data not shown). Expression of PP2A subunit C was also not different but phosphorylation level of PP2A-C on Tyr307, an indicator of PP2A inactivation, was lowered in the HFD group when compared to LFD. UT supplementation in the HFD significantly enhanced this phosphorylation compared to the HFD (P < 0.01; Fig. 4c). Methylation of PP2A-C on Leu309, also an indicator of PP2A catalytic activity, was higher in the HFD group compared to LFD. UT supplementation in the HFD significantly lowered this methylation (P < 0.01; Fig. 4c).

Ceramide levels and PP2A protein activity and expression in cultured myotube. As expected, exposure of myotubes to FFAs increased ceramide levels by more than one fold (Fig. 5a) and enhanced PP2A activity (Fig. 5b). Co-incubation with FFAs and UT or okadaic acid had no effect on ceramide accumulation but lowered PP2A activity compared to the FFA treatment only (P < 0.01; Fig. 5a,b). FFAs and UT had no effect on protein expression of PP2A subunits A, B and C (Fig. 5c,d). However, FFAs significantly lowered PP2A-C phosphorylation on Tyr307 and enhanced methylation on Leu309 (P < 0.01; Fig. 5d lanes 1 and 2 vs lanes 3 and 4). Co-incubation of FFAs with UT enhanced PP2A-C Tyr307 phosphorylation and lowered Leu309 methylation

<table>
<thead>
<tr>
<th></th>
<th>LFD</th>
<th>HFD</th>
<th>HFD/UT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose tolerance test (IPGT)</td>
<td>69,508 ± 1101</td>
<td>97,860 ± 2103</td>
<td>85,808 ± 1903</td>
</tr>
<tr>
<td>Insulin tolerance test (IPIT)</td>
<td>23,878 ± 967</td>
<td>34,258 ± 1105</td>
<td>27,440 ± 589</td>
</tr>
</tbody>
</table>

Table 2. Values of Area under the curve. *significantly different with HFD.
compared to FFA treatment alone (P < 0.01; Fig. 5d; lanes 3 and 4 vs lanes 5 and 6). Incubation with UT only enhanced PP2A-C Tyr307 phosphorylation compared to the vehicle only treatment (P < 0.01; Fig. 5d; lanes 1 and 2 vs. lanes 7 and 8).

Discussion
In this study, we report the effects of a UT extract on plasma glucose homeostasis and insulin signaling in skeletal muscle tissues from mice fed a high-fat diet. Consistent with prior reports in rats10–13, we show that supplementing a high fat diet with UT enhances glucose homeostasis. Several studies have demonstrated that excess dietary lipids results in accumulation of lipid metabolites particularly ceramides that impair insulin signaling in insulin sensitive tissues5–7,19–21. To date, there are no reported studies on the effects of UT on skeletal muscle insulin sensitivity. We show that UT supplementation enhances skeletal muscle insulin sensitivity despite the accumulation of ceramides. Furthermore, UT attenuated FFA induced insulin resistance in myotubes by enhancing Akt phosphorylation despite the accumulation of ceramides. We further show that the enhanced Akt phosphorylation is accompanied with a reduction in HFD or FFA induced hyperactivity of PP2A, the phosphatase that is activated by ceramides and is responsible for dephosphorylating Akt.

The connection between insulin resistance and obesity is well established. Obesity leads to elevated levels of circulating FFAs that contribute to insulin resistance by promoting excessive deposition lipid metabolites in tissues not suited for fat storage such as skeletal muscle5–7,18–20. Here in we report on the effects of UT on glucose homeostasis and insulin signaling in skeletal muscle of a robust pre-diabetes model; high fat fed C57BL/6J mice. These mice developed mild to moderate hyperglycemia, post- glucose load hyperglycemia, fasting hyperinsulinemia, and a diminished insulin response after 12 weeks feeding. Supplementation of the HFD with UT improved glucose homeostasis and insulin sensitivity as assessed by, IPIT and HOMA-IR without affecting food intake, body weight or body composition (Tables 1 and 2; Fig. 1).

We evaluated the effects of UT in skeletal muscle because it is the site of majority of insulin-stimulated glucose disposal and insulin resistance in skeletal muscle can be evident decades before β-cell failure and overt hyperglycemia22,23. Supplementation of the HFD with UT abated insulin resistance as evidenced by enhanced levels of Akt phosphorylation on Ser473 and Thr308 (Fig. 2). Akt is a serine/threonine kinase that mediates many effects of insulin including glucose uptake and metabolism. Akt activation depends on regulatory mechanisms that require dual phosphorylation on Ser473 and Thr308 by PDK1 and the TORC2 complex respectively and translocation to the
By moderating these effects on Akt, UT enhanced insulin sensitivity in skeletal muscle. The *in vitro* data complemented the *in vivo* data by showing that UT attenuated the inhibitory effects of FFAs on Akt phosphorylation at Ser 473 and Thr308 and insulin stimulated glycogen synthesis; an essential downstream function that results from the phosphorylation and inactivation of GSK-3 by Akt. Activated GSK-3 reduces glycogen synthesis and plays a dominant role in inducing skeletal muscle insulin resistance24. UT enhanced glucose uptake in both FFA treated and control cells. We included a treatment with okadaic acid (OK) a naturally occurring polyether that enhances Akt phosphorylation by inhibiting PP2A. UT effects were comparable to those of OK in attenuating the ability of FFAs to induce insulin resistance in skeletal muscle cells (Fig. 3).

Among lipid metabolites that accumulate with high fat diets, ceramides have been shown to be the most active in negatively regulating insulin signaling by blocking the activation of Akt without affecting upstream signaling events5–7,19–21. Akt is dependent on stimulatory signals from the insulin receptor for activation but is simultaneously under negative control by phosphatases particularly PP2A15–17,21,25. Studies in insulin responsive cells, have implicated hyperactivity of PP2A in the pathogenesis of Akt dephosphorylation, leading to attenuation of glucose transport stimulation17,20. PP2A is a serine/threonine phosphatase that leaves Akt dephosphorylated and unable to translocate to the plasma membrane. In contrast to other lipids, ceramides have been shown to be specific activators of PP2A25. Besides activating PP2A, ceramides that accumulate in caveolin-enriched domains of the cell membrane also interfere with PKCzeta catalyzed phosphorylation of Akt thus preventing it from participating in downstream insulin receptor signaling2. Insulin inhibits PP2A activity but this effect is diminished in diabetic models25. Our data shows that UT attenuated the ability of accumulated ceramides to induce PP2A hyperactivity without lowering ceramide levels in muscle tissue and C2C12 myotubes (Figs 4 and 5). We concluded that inhibition of PP2A activity in skeletal muscle by UT plays a role in the significant increase in Akt phosphorylation observed despite the increased levels of ceramides.

The major finding and one that requires a mechanism is UT how reduces PP2A activity. We therefore evaluated UT effects on PP2A expression and posttranslational modification. PP2A is a heterotrimeric complex
comprised of a structural or scaffolding subunit A, a regulatory subunit B, and a catalytic subunit C. It controls the phosphorylation of a wide range of substrates but gains specificity through the targeting regulatory subunit B. Phosphorylation of the catalytic subunit at Tyr307 results in substantial reduction of activity. The catalytic subunit is also subject to methyl esterification of its C terminus on Leu-309. This methylation activates the enzyme. Inhibiting methylation contributes to a decrease in activity. We show that the enhanced PP2A activity in HFD mice muscle resulted from increased Leu309 methylation and decreased Tyr307 phosphorylation of the catalytic subunit. UT supplementation reduced Leu309 methylation and increased Tyr307 phosphorylation thus decreasing overall activity of the enzyme.

A limitation of our study is that we have not elucidated the bioactive components of UT. Identification of the active components of UT will be an important next step for determining its potential as a metabolically beneficial botanical supplement for obesity induced insulin resistance. Since stinging nettle has a history of human use as a food, the effects of its components are unlikely to pose toxicity issues. This was corroborated in this study. Based on work done using the whole extract we conclude that UT components attenuate obesity induced insulin resistance through mechanisms that enhance Akt phosphorylation and its downstream effects without affecting food intake, body weight or body composition.

References

Figure 5. UT extract attenuates FFA induced hyperactivity of PP2A and enhances Akt phosphorylation in C2C12 myotubes. Fully differentiated C2C12 myotubes were incubated with palmitate (250 uM) with or without UT (5 ug/ml) or 10 nM okadaic acid (OK) for 16 hours. (a) Cells were extracted for lipids by the Folch partition and ceramide quantities determined by tandem mass spectrometry (LC/MS/MS). (b) Cell lysates were separated by SDS-PAGE and analyzed by immune blot analysis for PP2A-A and PP2A-B protein expression and (d) PP2A-C protein expression, PP2A-C tyrosine phosphorylation and PP2A-C-Leucine methylation. Each panel represents an experiment independently repeated three times on different batches of myotubes. * denotes significant difference with FFA only treatment (P < 0.05). # denotes significant difference with the untreated control treatment (P < 0.05).


Acknowledgements

This work was supported by P50AT002776-01 from the National Center for Complementary and Alternative Medicine and the Office of Dietary Supplements, which funds the Botanical Research Center of Pennington Biomedical Research Center and the Biotech Center of Rutgers University. WTC was also supported in part by U54 GM104940 from the NIH NIGMS. The study utilized resources provided by NIH Grant P50 AT002776. DO was supported in part by a diversity supplement on the same grant.

Author Contributions

D.O.-Designed the study, data collection, prepared and edited manuscript. Y.Y.-Data collection in animal study. D.R.-Plant collection, vouchering and extract preparation. J.S.-Data analysis and manuscript preparation. W.C.-Designed the study and edited manuscript.

Additional Information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Obanda, D. N. *et al.* An extract of *Urtica dioica* L. mitigates obesity induced insulin resistance in mice skeletal muscle via protein phosphatase 2A (PP2A). *Sci. Rep.* **6**, 22222; doi: 10.1038/srep22222 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/